Abstract: There are provided substituted 4-carboxamido-isoindolinone derivatives which selectively inhibit the activity of poly (ADP-ribose) polymerase PARP-I with respect to poly (ADP-ribose) polymerase P ARP-2. The compounds of this invention are therefore useful in treating diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds.

Abstract: There are provided substituted 4-carboxamido-isoindolinone derivatives which selectively inhibit the activity of poly (ADP-ribose) polymerase PARP-1 with respect to poly (ADP-ribose) polymerase P ARP-2. The compounds of this invention are therefore useful in treating diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds.

Abstract: There are provided substituted 4-carboxamido-isoindolinone derivatives which selectively inhibit the activity of poly (ADP-ribose) polymerase PARP-I with respect to poly (ADP-ribose) polymerase P ARP-2. The compounds of this invention are therefore useful in treating diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of in-flammation. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds.

Abstract: There are provided substituted 4-carboxamido-isoindolinone derivatives which selectively inhibit the activity of poly (ADP-ribose) polymerase PARP-1 with respect to poly (ADP-ribose) polymerase P ARP-2. The compounds of this invention are therefore useful in treating diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of in-flammation. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds.

Abstract: There are provided substituted 4-carboxamido-isoindolinone derivatives which selectively inhibit the activity of poly (ADP-ribose) polymerase PARP-I with respect to poly (ADP-ribose) polymerase P ARP-2. The compounds of this invention are therefore useful in treating diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of in-flammation. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds.

Abstract: There are provided substituted 4-carboxamido-isoindolinone derivatives which selectively inhibit the activity of poly (ADP-ribose) polymerase PARP-I with respect to poly (ADP-ribose) polymerase P ARP-2. The compounds of this invention are therefore useful in treating diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of in-flammation. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds.

Abstract: There are provided substituted 4-carboxamido-isoindolinone derivatives which selectively inhibit the activity of poly (ADP-ribose) polymerase PARP-1 with respect to poly (ADP-ribose) polymerase PARP-2. The compounds of this invention are therefore useful in treating diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds.

Abstract: In an embodiment, set forth by way of example and not limitation, an integrated circuit includes charge pump circuitry formed on an integrated circuit (IC) chip, a first protective circuit formed on the integrated circuit chip and coupling the first output node to a first IC port, a second protective circuit formed on the integrated circuit chip and coupling the second output node to a second IC port, and a third protective circuit formed on the integrated circuit chip and coupling the power input node to a power input IC port.

Abstract: A method for detecting and classifying powered devices in power over Ethernet/non-power over Ethernet applications is described. In one or more implementations, the method includes deactivating a non-power over Ethernet component for a predetermined time period. The method also includes activating an isolation switch of a powered device after the predetermined time period has elapsed since no characteristic impedance associated with the powered device has been detected.

Abstract: A system for controlling the operation of isolation transistors in high power Power over Ethernet (PoE) networks to achieve greater power delivery to a load is disclosed. In one or more implementations, the system includes a first power over Ethernet (PoE) powered device controller configured to control power supply to a load, and a second PoE powered device controller coupled to the load and to the first PoE powered device controller. The second PoE powered device controller is connected to the first PoE powered device controller using a shared connection interface and is configured to control power supply to the load. The shared connection interface is configured to synchronize the first PoE powered device controller and the second PoE powered device controller to deliver power at least substantially contemporaneously to the load.

Abstract: A method is disclosed to at least partially prevent back powering of power sourcing equipment. In one or more implementations, the method includes detecting a magnitude of current through a current sensor, such as a transistor and/or a resistor. The active FET bridge is configured to rectify input power supplied by power sourcing equipment to a power over Ethernet (PoE) powered device. The method also includes causing the transistor to transition from a closed configuration to an open configuration to at least substantially prevent current flow through the transistor when the magnitude of current is below a predefined threshold to at least substantially prevent back powering of the PSE.

Abstract: A system for sinking maintain power signature (MPS) current to a rectifier bridge from a powered device (PD) controller in a Power over Ethernet (PoE) network is disclosed. In one or more implementations, the system includes a rectifier bridge configured to electrically connect to Power over Ethernet power sourcing equipment for receiving power from the power sourcing equipment. The system also includes a powered device controller operatively connected to the rectifier bridge and configured to control power supplied to a load. The load is configured to receive power from the power sourcing equipment and a second power source. The powered device controller is configured to source maintain power signature current to the power sourcing equipment using an input of the rectifier bridge when the second power source is furnishing power to the load.

Abstract: A system includes a driver circuit, a modulator circuit, and a reset circuit. The driver circuit drives a plurality of light emitting diodes via a switch. The switch is controlled by a first signal having a first frequency. The driver circuit controls brightness of the light emitting diodes based on a second signal including a plurality of pulses. The modulator circuit modulates the first signal using a direct sequence spread spectrum modulation. The direct sequence spread spectrum modulation uses a sequence generated based on the first signal. The reset circuit resets the modulator circuit at each of the plurality of pulses of the second signal. The modulator circuit repeats the sequence at each of the plurality of pulses of the second signal.

Abstract: There are provided substituted 3-phenyl-isoquinolin-1(2H)-one derivatives which selectively inhibit the activity of poly(ADP-ribose) polymerase PARP-1 with respect to poly(ADP-ribose) polymerase PARP-2. The compounds of the present invention are therefore useful in treating diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds.

Abstract: A power supply protection system including a first metal oxide field effect transistor (MOSFET) having a first source, a first drain coupled to an input node, and a first gate; a second MOSFET having a second source coupled to the first source, a second drain coupled to an output node and a second gate coupled to the first gate, whereby the first MOSFET and the second MOSFET are coupled back-to-back; a zener diode coupled between the first and second sources and the first and second gates; and charge pump circuitry coupled across the zener diode, whereby a voltage on the first and second gates is boosted with respect to the voltage on the first and second sources.

Abstract: There are provided substituted 4-carboxamido-isoindolinone derivatives which selectively inhibit the activity of poly (ADP-ribose) polymerase PARP-1 with respect to poly (ADP-ribose) polymerase PARP-2. The compounds of this invention are therefore useful in treating diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds.

Abstract: A system includes a driver circuit, a modulator circuit, and a reset circuit. The driver circuit drives a plurality of light emitting diodes via a switch. The switch is controlled by a first signal having a first frequency. The driver circuit controls brightness of the light emitting diodes based on a second signal including a plurality of pulses. The modulator circuit modulates the first signal using a direct sequence spread spectrum modulation. The direct sequence spread spectrum modulation uses a sequence generated based on the first signal. The reset circuit resets the modulator circuit at each of the plurality of pulses of the second signal. The modulator circuit repeats the sequence at each of the plurality of pulses of the second signal.

Abstract: There are provided 3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivatives which selectively inhibit the activity of poly (ADP-ribose) polymerase PARP-1 with respect to poly (ADP-ribose) polymerase PARP-2. The compounds of this invention are therefore useful in treating diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds.

Abstract: There are provided substituted isoquinolin-1(2H)-one derivatives which selectively inhibit the activity of poly (ADP-ribose) polymerase PARP-1 with respect to poly (ADP-ribose) polymerase PARP-2. The compounds of the present invention are therefore useful in treating diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds. A screening method for the identification of compounds capable of binding several PARP proteins, as well the probes used in such method, are further objects of the invention.

Abstract: Compounds which are 4,7-disubstituted derivatives of 3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-one compounds, or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, viral infection, prevention of AIDS development in HIV-infected individuals, cell proliferative disorders, autoimmune and neurodegenerative disorders; also disclosed is a process under Solid Phase Synthesis conditions for preparing the compounds of the invention and chemical libraries comprising a plurality of them.